BR9807974A - Composição farmacêutica para liberação prolongada de um derivado de eritromicina no ambiente gastrointestinal, e, processo para utilizar a mesma - Google Patents
Composição farmacêutica para liberação prolongada de um derivado de eritromicina no ambiente gastrointestinal, e, processo para utilizar a mesmaInfo
- Publication number
- BR9807974A BR9807974A BR9807974-3A BR9807974A BR9807974A BR 9807974 A BR9807974 A BR 9807974A BR 9807974 A BR9807974 A BR 9807974A BR 9807974 A BR9807974 A BR 9807974A
- Authority
- BR
- Brazil
- Prior art keywords
- erythromycin derivative
- composition
- pharmaceutical composition
- prolonged release
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
"COMPOSIçãO FARMACêUTICA PARA LIBERAçãO PROLONGADA DE UM DERIVADO DE ERITROMICINA NO AMBIENTE GASTROINTESTINAL, E, PROCESSO PARA UTILIZAR A MESMA". é descrita uma composição farmacêutica para liberação prolongada de um derivado de eritromicina no ambiente gastrointestinal. A composição compreende um derivado de eritromicina e um polímero farmaceuticamente aceitável, de modo que, quando ingerida oralmente, a composição induz C~ max~ estatística e significativamente mais baixa no plasma do que uma composição de liberação imediata do derivado de eritromicina, enquanto mantendo a biodisponibilidade e concentração mínima substancialmente equivalentes à da composição de liberação imediata do derivado de eritromicina quando de múltipla dosagem. As composições da invenção têm um perfil de paladar melhorado e reduzidos efeitos colaterais gastrointestinais, em comparação com aqueles da composição de liberação imediata.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/838,900 US6010718A (en) | 1997-04-11 | 1997-04-11 | Extended release formulations of erythromycin derivatives |
PCT/US1998/004373 WO1998046239A1 (en) | 1997-04-11 | 1998-03-06 | Extended release formulations of erythromycin derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9807974A true BR9807974A (pt) | 2000-03-08 |
Family
ID=25278344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9807974-3A BR9807974A (pt) | 1997-04-11 | 1998-03-06 | Composição farmacêutica para liberação prolongada de um derivado de eritromicina no ambiente gastrointestinal, e, processo para utilizar a mesma |
Country Status (29)
Country | Link |
---|---|
US (1) | US6010718A (pt) |
EP (2) | EP1340495B1 (pt) |
JP (2) | JP4394754B2 (pt) |
KR (1) | KR100484559B1 (pt) |
CN (1) | CN100408044C (pt) |
AR (1) | AR012358A1 (pt) |
AT (1) | ATE253371T1 (pt) |
AU (1) | AU737324B2 (pt) |
BG (1) | BG65188B1 (pt) |
BR (1) | BR9807974A (pt) |
CA (1) | CA2285266C (pt) |
CO (1) | CO4940403A1 (pt) |
CZ (1) | CZ294333B6 (pt) |
DE (1) | DE69819481T2 (pt) |
DK (1) | DK0973527T3 (pt) |
ES (1) | ES2205454T3 (pt) |
HK (1) | HK1027023A1 (pt) |
HU (1) | HUP0001382A3 (pt) |
IL (3) | IL131616A0 (pt) |
NO (1) | NO994946D0 (pt) |
NZ (3) | NZ537410A (pt) |
PL (2) | PL402949A1 (pt) |
PT (1) | PT973527E (pt) |
SA (1) | SA98190065B1 (pt) |
SK (2) | SK288127B6 (pt) |
TR (2) | TR199902149T2 (pt) |
TW (1) | TW576743B (pt) |
WO (1) | WO1998046239A1 (pt) |
ZA (1) | ZA982916B (pt) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6551616B1 (en) * | 1997-04-11 | 2003-04-22 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
AU773863B2 (en) * | 1997-04-11 | 2004-06-10 | Bgp Products Operations Gmbh | Extended release formulations of erythromycin derivatives |
US6099859A (en) * | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
TR200000054A2 (tr) * | 2000-01-05 | 2001-08-21 | Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ | Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları. |
US6544555B2 (en) * | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US6565882B2 (en) * | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
AU2578701A (en) * | 2000-02-29 | 2001-09-12 | Teva Pharma | Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same |
DK1267840T3 (da) * | 2000-03-28 | 2009-09-07 | Sandoz Ag | Granulerede partikler med maskeret smag |
IN192748B (pt) * | 2000-08-29 | 2004-05-15 | Ranbaxy Lab Ltd | |
US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
MXPA03003146A (es) * | 2000-10-13 | 2004-12-06 | Advancis Pharmaceuticals | Derivados de eritromicina de liberacion prolongada. |
US20020068078A1 (en) * | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US20060034922A1 (en) * | 2000-11-03 | 2006-02-16 | Andrx Labs, Llc | Controlled release metformin compositions |
US6866866B1 (en) * | 2000-11-03 | 2005-03-15 | Andrx Labs, Llc | Controlled release metformin compositions |
US6790459B1 (en) | 2000-11-03 | 2004-09-14 | Andrx Labs, Llc | Methods for treating diabetes via administration of controlled release metformin |
US20020197314A1 (en) * | 2001-02-23 | 2002-12-26 | Rudnic Edward M. | Anti-fungal composition |
EP1423097A1 (en) * | 2001-08-29 | 2004-06-02 | Ranbaxy Laboratories, Ltd. | Controlled release formulation of clarithromycin or tinidazol |
US6673369B2 (en) | 2001-08-29 | 2004-01-06 | Ranbaxy Laboratories Limited | Controlled release formulation |
US20050191359A1 (en) * | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
US20050233003A1 (en) * | 2001-09-28 | 2005-10-20 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid |
US20050249786A1 (en) * | 2001-09-28 | 2005-11-10 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds |
US6878693B2 (en) * | 2001-09-28 | 2005-04-12 | Solubest Ltd. | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
US20050227911A1 (en) * | 2001-09-28 | 2005-10-13 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules |
CA2465405A1 (en) * | 2001-11-02 | 2003-05-08 | Wockhardt Limited | Controlled release compositions for macrolide antimicrobial agents |
US7700851B2 (en) * | 2001-11-13 | 2010-04-20 | U.S. Smokeless Tobacco Company | Tobacco nicotine demethylase genomic clone and uses thereof |
AU2003225837B2 (en) * | 2002-03-15 | 2008-11-06 | Forest Laboratories Holdings Limited | NE and 5-HT reuptake inhibitors for treating visceral pain syndromes |
WO2003099214A2 (en) * | 2002-05-23 | 2003-12-04 | Andrx Corporation | Biguanide formulations |
AU2003245504A1 (en) * | 2002-06-14 | 2003-12-31 | Andrx Corporation | Pharmaceutical compositions for drugs having ph-dependentsolubility |
US20040121010A1 (en) * | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
US20060003004A1 (en) * | 2002-10-25 | 2006-01-05 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
US20040191302A1 (en) | 2003-03-28 | 2004-09-30 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
US20040131662A1 (en) | 2003-11-12 | 2004-07-08 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
US9561182B2 (en) * | 2003-08-22 | 2017-02-07 | Cure Pharmaceutical Corporation | Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals |
US8999372B2 (en) * | 2002-11-14 | 2015-04-07 | Cure Pharmaceutical Corporation | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use |
AU2004207578B2 (en) * | 2003-01-28 | 2007-06-28 | Collegium Pharmaceutical, Inc. | Multiparticulate compositions of milnacipran for oral administration |
US20040185097A1 (en) * | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
JP2006528689A (ja) * | 2003-05-06 | 2006-12-21 | ムルイェ、ニルマル | エリスロマイシン誘導体の徐放製剤 |
US7063862B2 (en) * | 2003-06-03 | 2006-06-20 | Biokey, Inc. | Pharmaceutical composition and method for treating |
EP1638529B1 (en) * | 2003-06-16 | 2016-08-10 | ANDRX Pharmaceuticals, LLC. | Oral extended-release composition |
US20050053658A1 (en) * | 2003-09-09 | 2005-03-10 | Venkatesh Gopi M. | Extended release systems for macrolide antibiotics |
US8313776B2 (en) * | 2003-07-21 | 2012-11-20 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
AU2004258953B2 (en) * | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
EP1648418A4 (en) * | 2003-07-21 | 2011-11-16 | Middlebrook Pharmaceuticals Inc | ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION |
EP1653925A1 (en) * | 2003-08-11 | 2006-05-10 | Advancis Pharmaceutical Corporation | Robust pellet |
AU2004264356B2 (en) | 2003-08-12 | 2011-01-27 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
JP5686494B2 (ja) * | 2003-08-29 | 2015-03-18 | シオノギ インコーポレイテッド | 抗生物質製剤、その使用法及び作成方法 |
WO2005023221A1 (en) * | 2003-09-05 | 2005-03-17 | Ranbaxy Laboratories Limited | Clarithromycin formulations having improved biovailability |
WO2005027877A1 (en) * | 2003-09-15 | 2005-03-31 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
US20050084540A1 (en) * | 2003-10-17 | 2005-04-21 | Indranil Nandi | Taste masking antibiotic composition |
US8168228B2 (en) * | 2003-10-17 | 2012-05-01 | Sandoz Ag | Antibiotic clarithromycin micropellet compositions |
ES2405404T3 (es) | 2003-10-29 | 2013-05-31 | Wyeth Llc | Composiciones farmacéuticas de liberación sostenida que comprenden aplindore y sus derivados |
US20050101547A1 (en) * | 2003-11-06 | 2005-05-12 | Sadatrezaei Mohsen | Stabilized azithromycin composition |
WO2005053653A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride |
CA2549225A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride |
WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
BRPI0416534A (pt) * | 2003-12-04 | 2007-01-09 | Pfizer Prod Inc | composições multiparticuladas com estabilidade melhorada |
US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
RU2006119453A (ru) * | 2003-12-04 | 2007-12-20 | Пфайзер Продактс Инк. (Us) | Получение посредством основанных на применении жидкостей способов лекарственные формы азитромицина с большим количеством частиц |
WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
EP1691787B1 (en) * | 2003-12-04 | 2008-07-02 | Pfizer Products Inc. | Method for making pharmaceutical multiparticulates |
US7943585B2 (en) | 2003-12-22 | 2011-05-17 | Sandoz, Inc. | Extended release antibiotic composition |
EP1701705A4 (en) * | 2003-12-24 | 2007-08-08 | Advancis Pharmaceutical Corp | IMPROVED ABSORPTION OF MODIFIED RELEASE DOSAGE FORMS |
MXPA06010805A (es) * | 2004-03-24 | 2006-12-19 | Lupin Ltd | Formulacion de claritromicina de libracion prolongada. |
US20050260263A1 (en) * | 2004-05-18 | 2005-11-24 | Panion & Bf Biotech Inc. | Sustained release formulation for sparingly soluble main drugs |
KR101122096B1 (ko) * | 2004-05-20 | 2012-03-15 | 주식회사종근당 | 쓴맛을 차폐하면서 우수한 용출률을 보이는클라리스로마이신의 약제학적 조성물 및 그의 제조 방법 |
KR100621342B1 (ko) * | 2004-06-22 | 2006-09-18 | (주)다산메디켐 | 클래리스로마이신-함유 약제학적 조성물 및 그의 제조방법 |
JP2008505124A (ja) * | 2004-07-02 | 2008-02-21 | アドバンシス ファーマスーティカル コーポレイション | パルス送達用錠剤 |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US8778924B2 (en) * | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
TW200800233A (en) * | 2006-04-28 | 2008-01-01 | Shionogi & Amp Co Ltd | A coated preparation of macrolide antibiotics |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
JP2009539866A (ja) * | 2006-06-05 | 2009-11-19 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換エリスロマイシンアナログの調製および有用性 |
EP2283824B1 (en) | 2009-07-30 | 2017-04-19 | Special Products Line S.p.A. | Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin |
EP2671571A1 (en) | 2012-06-05 | 2013-12-11 | Sanovel Ilac Sanayi ve Ticaret A.S. | Controlled-release formulations of clarithromycin |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3870790A (en) * | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
US4226849A (en) * | 1979-06-14 | 1980-10-07 | Forest Laboratories Inc. | Sustained release therapeutic compositions |
US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
ATE66143T1 (de) * | 1985-01-11 | 1991-08-15 | Abbott Lab | Feste zubereitung mit langsamer freisetzung. |
FR2585948B1 (fr) * | 1985-08-06 | 1988-12-16 | Pf Medicament | Procede de fabrication de comprimes d'indometacine |
US4808411A (en) * | 1987-06-05 | 1989-02-28 | Abbott Laboratories | Antibiotic-polymer compositions |
US4925675A (en) | 1988-08-19 | 1990-05-15 | Himedics, Inc. | Erythromycin microencapsulated granules |
JP3265680B2 (ja) * | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
US5393765A (en) * | 1993-12-13 | 1995-02-28 | Hoffmann-La Roche Inc. | Pharmaceutical compositions with constant erosion volume for zero order controlled release |
JP2977907B2 (ja) * | 1994-05-06 | 1999-11-15 | ファイザー・インコーポレーテッド | アジスロマイシンの放出調節された剤形 |
JPH0995440A (ja) * | 1995-09-29 | 1997-04-08 | Roussel Morishita Kk | 徐放性製剤およびその製造方法 |
US5919489A (en) * | 1995-11-01 | 1999-07-06 | Abbott Laboratories | Process for aqueous granulation of clarithromycin |
US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
US5972389A (en) * | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
-
1997
- 1997-04-11 US US08/838,900 patent/US6010718A/en not_active Expired - Lifetime
-
1998
- 1998-03-06 JP JP54388298A patent/JP4394754B2/ja not_active Expired - Fee Related
- 1998-03-06 DK DK98907722T patent/DK0973527T3/da active
- 1998-03-06 CN CNB03157906XA patent/CN100408044C/zh not_active Expired - Fee Related
- 1998-03-06 PL PL402949A patent/PL402949A1/pl not_active Application Discontinuation
- 1998-03-06 KR KR10-1999-7009335A patent/KR100484559B1/ko not_active IP Right Cessation
- 1998-03-06 NZ NZ537410A patent/NZ537410A/en not_active IP Right Cessation
- 1998-03-06 TR TR1999/02149T patent/TR199902149T2/xx unknown
- 1998-03-06 TR TR2007/07263T patent/TR200707263T2/xx unknown
- 1998-03-06 IL IL13161698A patent/IL131616A0/xx unknown
- 1998-03-06 PT PT98907722T patent/PT973527E/pt unknown
- 1998-03-06 PL PL98336142A patent/PL336142A1/xx not_active IP Right Cessation
- 1998-03-06 EP EP03008281.2A patent/EP1340495B1/en not_active Expired - Lifetime
- 1998-03-06 WO PCT/US1998/004373 patent/WO1998046239A1/en active Application Filing
- 1998-03-06 SK SK5021-2010A patent/SK288127B6/sk not_active IP Right Cessation
- 1998-03-06 NZ NZ596215A patent/NZ596215A/xx not_active IP Right Cessation
- 1998-03-06 CZ CZ19993471A patent/CZ294333B6/cs not_active IP Right Cessation
- 1998-03-06 EP EP98907722A patent/EP0973527B1/en not_active Revoked
- 1998-03-06 AU AU63463/98A patent/AU737324B2/en not_active Expired
- 1998-03-06 ES ES98907722T patent/ES2205454T3/es not_active Expired - Lifetime
- 1998-03-06 AT AT98907722T patent/ATE253371T1/de active
- 1998-03-06 BR BR9807974-3A patent/BR9807974A/pt not_active Application Discontinuation
- 1998-03-06 SK SK1380-99A patent/SK288109B6/sk not_active IP Right Cessation
- 1998-03-06 NZ NZ337120A patent/NZ337120A/en not_active IP Right Cessation
- 1998-03-06 DE DE69819481T patent/DE69819481T2/de not_active Revoked
- 1998-03-06 HU HU0001382A patent/HUP0001382A3/hu unknown
- 1998-03-06 CA CA002285266A patent/CA2285266C/en not_active Expired - Lifetime
- 1998-03-17 TW TW087103954A patent/TW576743B/zh not_active IP Right Cessation
- 1998-04-06 ZA ZA982916A patent/ZA982916B/xx unknown
- 1998-04-07 AR ARP980101591A patent/AR012358A1/es not_active Application Discontinuation
- 1998-04-08 CO CO98019851A patent/CO4940403A1/es unknown
- 1998-05-16 SA SA98190065A patent/SA98190065B1/ar unknown
-
1999
- 1999-08-26 IL IL131616A patent/IL131616A/en not_active IP Right Cessation
- 1999-10-11 NO NO994946A patent/NO994946D0/no unknown
- 1999-11-05 BG BG103862A patent/BG65188B1/bg unknown
-
2000
- 2000-07-26 HK HK00104658A patent/HK1027023A1/xx not_active IP Right Cessation
-
2009
- 2009-01-07 JP JP2009001631A patent/JP5188994B2/ja not_active Expired - Fee Related
-
2012
- 2012-11-14 IL IL223035A patent/IL223035A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9807974A (pt) | Composição farmacêutica para liberação prolongada de um derivado de eritromicina no ambiente gastrointestinal, e, processo para utilizar a mesma | |
BR0010485A (pt) | Formulações de derivados de eritromicina de liberação prolongada | |
HUP0003323A2 (hu) | Vorikonazolt tartalmazó gyógyászati készítmények | |
BR9908488A (pt) | Composição farmacêutica de topiramato | |
BR0107147A (pt) | Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações | |
BR9908438A (pt) | Tabletes de desintegração rápida | |
ATE185562T1 (de) | Taxol derivate, deren herstellung und diese enthaltende pharmazeutischen zusammenstellungen | |
BR0015188A (pt) | Composições farmacêuticas | |
HUP0000138A2 (hu) | Szabályozott hatóanyag-leadású opioid analgetikumokat tartalmazó gyógyászati készítmények | |
BR9813827A (pt) | Analgésico opióide aplicável em mamìferos e método para impedir o uso oral abusivo de uma formulação opióide oral | |
BR0313424A (pt) | Forma de dosagem e processo para a preparação de uma forma de dosagem | |
BRPI0716439B8 (pt) | sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos | |
BR0005938A (pt) | Composição de dosagem oral com libaraçãoprolongada | |
BR0013355A (pt) | Tratamento com droga para a sìndrome da perna inquieta | |
CO5170471A1 (es) | Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio | |
BR9609012A (pt) | "novos nor-pregnanos para indução de efeitos hipolalâmicos" | |
TR199801861T2 (xx) | Farmas�tik olarak yararl� bile�imler. | |
AU9018898A (en) | Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments | |
BR0312728A (pt) | Formulação em tablete dispersìvel e processo para sua preparação | |
BR0110837A (pt) | Quimioterapia de combinação | |
BR0211198A (pt) | Composições farmacêuticas e seu uso | |
BR9809571A (pt) | Composição medicinal e processo para produzì-la | |
DE69608680D1 (de) | Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen | |
CO5540294A2 (es) | Una combinacion de un derivado de rapamicina y un agente alquilante seleccionado de ciclofosfamida y carmustina y composiciones que las contienen | |
BR9810337A (pt) | Utilização de um antagonista especìfico dos receptores 5ht2 para a preparação de medicamentos úteis no tratamento da sìndrome de apnéia do sono |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/7048 (2006.01), A61K 9/20 (2006.0 |